Shield Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Shield Therapeutics (LON:STX) Full Year 2023 Results

Key Financial Results

• Revenue: US$13.1m (up 142% from FY 2022).
• Net loss: US$33.3m (loss narrowed by 32% from FY 2022).
• US$0.05 loss per share (improved from US$0.21 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shield Therapeutics Revenues Disappoint

Revenue missed analyst estimates by 15%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in the United Kingdom.

Performance of the British Pharmaceuticals industry.

The company's shares are down 1.6% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Shield Therapeutics (2 can't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.